Unichem Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:07 am

Competitors of Unichem Laboratories Ltd

All Competitor Stocks of Unichem Laboratories Ltd

Quarterly Result

Last Updated: February 27, 2025, 11:27 pm

Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Sales, as of Dec 2024, the value is ₹533.00 Cr.. The value appears strong and on an upward trend. It has increased from 507.00 Cr. (Sep 2024) to ₹533.00 Cr., marking an increase of ₹26.00 Cr..
• For Expenses, as of Dec 2024, the value is ₹448.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 452.00 Cr. (Sep 2024) to ₹448.00 Cr., marking a decrease of 4.00 Cr..
• For Operating Profit, as of Dec 2024, the value is ₹86.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Sep 2024) to ₹86.00 Cr., marking an increase of ₹31.00 Cr..
• For OPM %, as of Dec 2024, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Sep 2024) to 16.00%, marking an increase of 5.00%.
• For Other Income, as of Dec 2024, the value is ₹14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Sep 2024) to ₹14.00 Cr., marking an increase of ₹5.00 Cr..
• For Interest, as of Dec 2024, the value is ₹7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Sep 2024) to ₹7.00 Cr., marking an increase of ₹2.00 Cr..
• For Depreciation, as of Dec 2024, the value is ₹31.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 32.00 Cr. (Sep 2024) to ₹31.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Dec 2024, the value is ₹62.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Sep 2024) to ₹62.00 Cr., marking an increase of ₹35.00 Cr..
• For Tax %, as of Dec 2024, the value is 6.00%. The value appears to be improving (decreasing) as expected. It has decreased from 9.00% (Sep 2024) to 6.00%, marking a decrease of 3.00%.
• For Net Profit, as of Dec 2024, the value is ₹58.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Sep 2024) to ₹58.00 Cr., marking an increase of ₹33.00 Cr..
• For EPS in Rs, as of Dec 2024, the value is 8.22. The value appears strong and on an upward trend. It has increased from ₹3.50 (Sep 2024) to 8.22, marking an increase of ₹4.72.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:30 pm

Balance Sheet

Last Updated: November 14, 2024, 6:38 pm

Below is a detailed analysis of the balance sheet data for Unichem Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹14.00 Cr..
• For Reserves, as of Sep 2024, the value is ₹2,387.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,348.00 Cr. (Mar 2024) to ₹2,387.00 Cr., marking an increase of 39.00 Cr..
• For Borrowings, as of Sep 2024, the value is ₹300.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹248.00 Cr. (Mar 2024) to ₹300.00 Cr., marking an increase of 52.00 Cr..
• For Other Liabilities, as of Sep 2024, the value is ₹610.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹559.00 Cr. (Mar 2024) to ₹610.00 Cr., marking an increase of 51.00 Cr..
• For Total Liabilities, as of Sep 2024, the value is ₹3,311.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹3,169.00 Cr. (Mar 2024) to ₹3,311.00 Cr., marking an increase of 142.00 Cr..
• For Fixed Assets, as of Sep 2024, the value is ₹1,153.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,196.00 Cr. (Mar 2024) to ₹1,153.00 Cr., marking a decrease of 43.00 Cr..
• For CWIP, as of Sep 2024, the value is ₹145.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹123.00 Cr. (Mar 2024) to ₹145.00 Cr., marking an increase of 22.00 Cr..
• For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1.00 Cr. (Mar 2024) to ₹0.00 Cr., marking a decrease of 1.00 Cr..
• For Other Assets, as of Sep 2024, the value is ₹2,013.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,849.00 Cr. (Mar 2024) to ₹2,013.00 Cr., marking an increase of 164.00 Cr..
• For Total Assets, as of Sep 2024, the value is ₹3,311.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,169.00 Cr. (Mar 2024) to ₹3,311.00 Cr., marking an increase of 142.00 Cr..

Notably, the Reserves (₹2,387.00 Cr.) exceed the Borrowings (300.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 24, the value is -10.01. This value is below the healthy minimum of 5. It has increased from -28.72 (Mar 23) to -10.01, marking an increase of 18.71.
• For Diluted EPS (Rs.), as of Mar 24, the value is -10.01. This value is below the healthy minimum of 5. It has increased from -28.72 (Mar 23) to -10.01, marking an increase of 18.71.
• For Cash EPS (Rs.), as of Mar 24, the value is 6.07. This value is within the healthy range. It has increased from -7.13 (Mar 23) to 6.07, marking an increase of 13.20.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 335.54. It has decreased from 345.89 (Mar 23) to 335.54, marking a decrease of 10.35.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 335.54. It has decreased from 345.89 (Mar 23) to 335.54, marking a decrease of 10.35.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 242.15. It has increased from 190.75 (Mar 23) to 242.15, marking an increase of 51.40.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 18.73. This value is within the healthy range. It has increased from -0.99 (Mar 23) to 18.73, marking an increase of 19.72.
• For PBIT / Share (Rs.), as of Mar 24, the value is 2.64. This value is within the healthy range. It has increased from -17.11 (Mar 23) to 2.64, marking an increase of 19.75.
• For PBT / Share (Rs.), as of Mar 24, the value is -8.76. This value is below the healthy minimum of 0. It has increased from -19.57 (Mar 23) to -8.76, marking an increase of 10.81.
• For Net Profit / Share (Rs.), as of Mar 24, the value is -10.01. This value is below the healthy minimum of 2. It has increased from -23.25 (Mar 23) to -10.01, marking an increase of 13.24.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -10.01. This value is below the healthy minimum of 2. It has increased from -28.72 (Mar 23) to -10.01, marking an increase of 18.71.
• For PBDIT Margin (%), as of Mar 24, the value is 7.73. This value is below the healthy minimum of 10. It has increased from -0.52 (Mar 23) to 7.73, marking an increase of 8.25.
• For PBIT Margin (%), as of Mar 24, the value is 1.09. This value is below the healthy minimum of 10. It has increased from -8.97 (Mar 23) to 1.09, marking an increase of 10.06.
• For PBT Margin (%), as of Mar 24, the value is -3.61. This value is below the healthy minimum of 10. It has increased from -10.26 (Mar 23) to -3.61, marking an increase of 6.65.
• For Net Profit Margin (%), as of Mar 24, the value is -4.13. This value is below the healthy minimum of 5. It has increased from -12.18 (Mar 23) to -4.13, marking an increase of 8.05.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is -4.13. This value is below the healthy minimum of 8. It has increased from -15.05 (Mar 23) to -4.13, marking an increase of 10.92.
• For Return on Networth / Equity (%), as of Mar 24, the value is -2.98. This value is below the healthy minimum of 15. It has increased from -8.30 (Mar 23) to -2.98, marking an increase of 5.32.
• For Return on Capital Employeed (%), as of Mar 24, the value is 0.75. This value is below the healthy minimum of 10. It has increased from -4.71 (Mar 23) to 0.75, marking an increase of 5.46.
• For Return On Assets (%), as of Mar 24, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -6.33 (Mar 23) to -2.22, marking an increase of 4.11.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.09. This value is within the healthy range. It has decreased from 0.12 (Mar 23) to 0.09, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.53. It has increased from 0.41 (Mar 23) to 0.53, marking an increase of 0.12.
• For Current Ratio (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has decreased from 2.49 (Mar 23) to 2.40, marking a decrease of 0.09.
• For Quick Ratio (X), as of Mar 24, the value is 1.40. This value is within the healthy range. It has decreased from 1.51 (Mar 23) to 1.40, marking a decrease of 0.11.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.12. This value is below the healthy minimum of 4. It has increased from 0.86 (Mar 23) to 1.12, marking an increase of 0.26.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 5.82. This value is within the healthy range. It has increased from -0.40 (Mar 23) to 5.82, marking an increase of 6.22.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.43. This value is below the healthy minimum of 3. It has increased from -8.45 (Mar 23) to 0.43, marking an increase of 8.88.
• For Enterprise Value (Cr.), as of Mar 24, the value is 3,504.16. It has increased from 2,147.12 (Mar 23) to 3,504.16, marking an increase of 1,357.04.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 23) to 2.06, marking an increase of 0.46.
• For EV / EBITDA (X), as of Mar 24, the value is 26.58. This value exceeds the healthy maximum of 15. It has increased from -304.97 (Mar 23) to 26.58, marking an increase of 331.55.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.02. This value is within the healthy range. It has increased from 1.52 (Mar 23) to 2.02, marking an increase of 0.50.
• For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Price / BV (X), as of Mar 24, the value is 1.46. This value is within the healthy range. It has increased from 0.83 (Mar 23) to 1.46, marking an increase of 0.63.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.02. This value is within the healthy range. It has increased from 1.52 (Mar 23) to 2.02, marking an increase of 0.50.
• For EarningsYield, as of Mar 24, the value is -0.02. This value is below the healthy minimum of 5. It has increased from -0.09 (Mar 23) to -0.02, marking an increase of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness